Skip to content
Clinical Trials – home

Vinzenz Von Paul Kliniken gGmbH

Verified siteinfo

Germany Boeheimstrasse 37, Sued, 70199 Stuttgart, Germany

  • 6 trials recruiting
  • Non-small cell lung cancer · Obesity · Triple negative breast cancer
  • Adult patients

About Specializations

Vinzenz Von Paul Kliniken gGmbH in Stuttgart, Germany specialises in clinical trials of conditions such as Non-small cell lung cancer, Obesity, Triple negative breast cancer, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Neoplasms and Digestive System Diseases

At Vinzenz Von Paul Kliniken gGmbH in Stuttgart, clinical research in oncology focuses on cancers affecting the digestive system, especially esophageal carcinoma. The trials are designed to assess whether adding new treatments can improve survival and disease control for people receiving standard cancer care.

  • Testing new treatment combinations for esophageal cancer
  • Evaluating whether therapy can improve event-free survival and overall outcomes
  • Comparing treatment effectiveness in patients receiving concurrent cancer care

This area reflects a strong interest in improving how advanced digestive tract cancers are managed, with a focus on better long-term results for patients.

Neoplasms and Female Reproductive System Diseases

Research at this hospital also includes studies in advanced epithelial ovarian cancer, a serious form of gynecologic cancer. These trials are aimed at understanding whether new combinations of therapy can extend the time before the disease progresses and support more effective first-line treatment.

  • Studying treatment strategies for advanced ovarian cancer
  • Assessing whether new therapies improve progression-free survival
  • Exploring better options for patients with BRCA-nonmutated disease

The work in this field is centered on improving outcomes for women with advanced cancer through more effective and targeted treatment approaches.

Hemic and Lymphatic Diseases

Clinical trials at Vinzenz Von Paul Kliniken gGmbH also address Chronic Lymphocytic Leukemia, a blood cancer that often requires careful treatment selection in older or medically complex patients. The research is focused on comparing therapeutic options to find approaches that are both effective and suitable for people with additional health conditions.

  • Evaluating new regimens for CLL
  • Measuring whether treatment improves progression-free survival
  • Comparing effectiveness in patients with coexisting medical conditions

These studies aim to refine care for hematologic malignancies by identifying treatments that balance disease control with tolerability.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Boeheimstrasse 37, Sued70199 StuttgartGermany
Recruiting now
6 trials
Conditions studied
15
Partner status
Verified site

More sites in StuttgartGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

15 clinical trials

Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:TheraOp gGmbH

Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:GBG Forschungs GmbH

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Cardiovascular disorder+3

Not yet recruiting

Study of Once‑Weekly Eloralintide (LY3841136 Sodium) in Adults with Obesity or Overweight, Type 2 Diabetes, and High Cardiovascular Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.